Correction: BRD4-specific PROTAC inhibits basal-like breast cancer partially through downregulating KLF5 expression
Yanjie Kong(Shenzhen Second People's Hospital), Ceshi Chen(Army Medical University), Chengang Zhou(Kunming Institute of Zoology), Meng Zhang(Shanxi University), Dewei Jiang(Kunming Institute of Zoology), Xia Liu(National Clinical Research), Wenjing Liu(Kunming University of Science and Technology), Gong Chen(Guangdong Pharmaceutical University), Chang Cai(Shenzhen Second People's Hospital), Wenfeng Peng(Shenzhen Second People's Hospital), Xiuyun Sun(Tsinghua University), Hailin Zhang(Wenzhou Medical University), Wenxin Lv(Tsinghua University), Yu Rao(Soochow University), Chuanyu Yang(Kunming Institute of Zoology), Tianlong Lan(Tsinghua University), Luzhen Wang(Nanjing Forestry University), Huang Haihui(Shenzhen Second People's Hospital)
Cited by 1
Related Papers
PROTACs: great opportunities for academia and industry
|Signal Transduction and Targeted Therapy|2019|627
PROTAC Technology: Opportunities and Challenges
|ACS Medicinal Chemistry Letters|2020|353
PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies
|Cell Research|2018|280
Chemistries of bifunctional PROTAC degraders
|Chemical Society Reviews|2022|270